Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma

Approximately 60% of patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL) are curable with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemoimmunotherapy. Epratuzumab (E) is an unlabeled anti-CD22 monoclonal antibody with efficacy in relapsed DLBCL. Th...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Micallef, Ivana N. M., Maurer, Matthew J., Wiseman, Gregory A., Nikcevich, Daniel A., Kurtin, Paul J., Cannon, Michael W., Perez, Domingo G., Soori, Gamini S., Link, Brian K., Habermann, Thomas M., Witzig, Thomas E.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2011
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3204728/
https://ncbi.nlm.nih.gov/pubmed/21673350
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-02-336990
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars